3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
140
INDUSTRY
127
NIH
7
NETWORK
5
FED
4
OTHER_GOV
2
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Genitourinary
2
Conditions
Prostatic Neoplasms
2
Sleep Initiation and Maintenance Disorders
1
Fatigue
1
Depression
1
Interventions
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
3
Zoledronic Acid
3
Saline Solution
3
Gemcitabine
3
enzalutamide
2
darolutamide
2
Radiosurgery
2
Magnetic Resonance Spectroscopy
2
Magnetic Resonance Imaging
2
LHRH, Ac-Nal(1)-Cpa(2)-Trp(3)-Arg(6)-Ala(10)-
2
Androgen Antagonists
2
Abiraterone Acetate
2
veliparib
1
toripalimab
1
bemarituzumab
1
avelumab
1
apatorsen
1
apalutamide
1
anlotinib
1
aldesleukin
1
abiraterone
1
Watchful Waiting
1
Videotape Recording
1
Urination
1
Ultrasound, High-Intensity Focused, Transrectal
1
Transurethral Resection of Prostate
1
Tacrolimus
1
Surveys and Questionnaires
1
Surgical Procedures, Operative
1
Sunitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
OTHER_GOV
×
enzalutamide
×
Genitourinary
×
Clear all
NCT07181122
2026-04-28
PRO-MIND
Ankara Etlik City Hospital
Recruiting
102 enrolled
NCT00268476
2023-04-18
STAMPEDE
Medical Research Council
Phase 2/3
Active not recruiting
11,992 enrolled